322 related articles for article (PubMed ID: 28397632)
21. Type 2 Diabetes Mellitus in Youth Exposed to Antipsychotics: A Systematic Review and Meta-analysis.
Galling B; Roldán A; Nielsen RE; Nielsen J; Gerhard T; Carbon M; Stubbs B; Vancampfort D; De Hert M; Olfson M; Kahl KG; Martin A; Guo JJ; Lane HY; Sung FC; Liao CH; Arango C; Correll CU
JAMA Psychiatry; 2016 Mar; 73(3):247-59. PubMed ID: 26792761
[TBL] [Abstract][Full Text] [Related]
22. The cost effectiveness of long-acting/extended-release antipsychotics for the treatment of schizophrenia: a systematic review of economic evaluations.
Achilla E; McCrone P
Appl Health Econ Health Policy; 2013 Apr; 11(2):95-106. PubMed ID: 23494934
[TBL] [Abstract][Full Text] [Related]
23. Weighing the evidence for harm from long-term treatment with antipsychotic medications: A systematic review.
Sohler N; Adams BG; Barnes DM; Cohen GH; Prins SJ; Schwartz S
Am J Orthopsychiatry; 2016; 86(5):477-85. PubMed ID: 26652608
[TBL] [Abstract][Full Text] [Related]
24. The Effect of Antipsychotic Treatment on Cortical Gray Matter Changes in Schizophrenia: Does the Class Matter? A Meta-analysis and Meta-regression of Longitudinal Magnetic Resonance Imaging Studies.
Vita A; De Peri L; Deste G; Barlati S; Sacchetti E
Biol Psychiatry; 2015 Sep; 78(6):403-12. PubMed ID: 25802081
[TBL] [Abstract][Full Text] [Related]
25. Effectiveness and cost of atypical versus typical antipsychotic treatment for schizophrenia in routine care.
Stargardt T; Weinbrenner S; Busse R; Juckel G; Gericke CA
J Ment Health Policy Econ; 2008 Jun; 11(2):89-97. PubMed ID: 18509216
[TBL] [Abstract][Full Text] [Related]
26. Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies.
Kishimoto T; Nitta M; Borenstein M; Kane JM; Correll CU
J Clin Psychiatry; 2013 Oct; 74(10):957-65. PubMed ID: 24229745
[TBL] [Abstract][Full Text] [Related]
27. Association between second-generation antipsychotic medication half-life and hospitalization in the community treatment of adult schizophrenia.
Broder MS; Bates JA; Jing Y; Hebden T; Forbes RA; Chang E
J Med Econ; 2012; 15(1):105-11. PubMed ID: 21991926
[TBL] [Abstract][Full Text] [Related]
28. Chlorpromazine versus every other antipsychotic for schizophrenia: a systematic review and meta-analysis challenging the dogma of equal efficacy of antipsychotic drugs.
Samara MT; Cao H; Helfer B; Davis JM; Leucht S
Eur Neuropsychopharmacol; 2014 Jul; 24(7):1046-55. PubMed ID: 24766970
[TBL] [Abstract][Full Text] [Related]
29. Safety and tolerability of antipsychotic co-treatment in patients with schizophrenia: results from a systematic review and meta-analysis of randomized controlled trials.
Galling B; Roldán A; Rietschel L; Hagi K; Walyzada F; Zheng W; Cao XL; Xiang YT; Kane JM; Correll CU
Expert Opin Drug Saf; 2016 May; 15(5):591-612. PubMed ID: 26967126
[TBL] [Abstract][Full Text] [Related]
30. Medication adherence and discontinuation of long-acting injectable versus oral antipsychotics in patients with schizophrenia or bipolar disorder.
Greene M; Yan T; Chang E; Hartry A; Touya M; Broder MS
J Med Econ; 2018 Feb; 21(2):127-134. PubMed ID: 28895758
[TBL] [Abstract][Full Text] [Related]
31. Viewpoint: do antipsychotics protect against early death? A critical view.
Whitaker R
Psychol Med; 2020 Dec; 50(16):2643-2652. PubMed ID: 33050955
[TBL] [Abstract][Full Text] [Related]
32. Clozapine versus typical neuroleptic medication for schizophrenia.
Wahlbeck K; Cheine M; Essali MA
Cochrane Database Syst Rev; 2000; (2):CD000059. PubMed ID: 10796289
[TBL] [Abstract][Full Text] [Related]
33. Do antipsychotic medications reduce or increase mortality in schizophrenia? A critical appraisal of the FIN-11 study.
De Hert M; Correll CU; Cohen D
Schizophr Res; 2010 Mar; 117(1):68-74. PubMed ID: 20060684
[TBL] [Abstract][Full Text] [Related]
34. First-generation antipsychotic long-acting injections v. oral antipsychotics in schizophrenia: systematic review of randomised controlled trials and observational studies.
Haddad PM; Taylor M; Niaz OS
Br J Psychiatry Suppl; 2009 Nov; 52():S20-8. PubMed ID: 19880913
[TBL] [Abstract][Full Text] [Related]
35. Antipsychotics and mortality in first-onset schizophrenia: prospective Finnish register study with 5-year follow-up.
Kiviniemi M; Suvisaari J; Koivumaa-Honkanen H; Häkkinen U; Isohanni M; Hakko H
Schizophr Res; 2013 Oct; 150(1):274-80. PubMed ID: 23953217
[TBL] [Abstract][Full Text] [Related]
36. Systematic review of long-acting injectables versus oral atypical antipsychotics on hospitalization in schizophrenia.
Lafeuille MH; Dean J; Carter V; Duh MS; Fastenau J; Dirani R; Lefebvre P
Curr Med Res Opin; 2014 Aug; 30(8):1643-55. PubMed ID: 24730586
[TBL] [Abstract][Full Text] [Related]
37. Impact of cannabis use and its cessation on the dosage and the efficacy of antipsychotic drugs in in- and outpatients with schizophrenia taking medication: A systematic review and meta-analysis.
Rault O; Romeo B; Butlen-Ducuing F; Rari E; Benyamina A; Martelli C
J Psychiatr Res; 2022 Dec; 156():713-721. PubMed ID: 36410310
[TBL] [Abstract][Full Text] [Related]
38. Do atypical antipsychotic drugs reduce the risk of ischemic heart disease and mortality? Possible role of 5-HT2A receptor blockade.
Blasco-Fontecilla H; Baca-Garcia E; de Leon J
Schizophr Res; 2010 Jun; 119(1-3):160-3. PubMed ID: 20053538
[TBL] [Abstract][Full Text] [Related]
39. Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia : a 12- and 24-month follow-up from the e-STAR database in Spain.
Olivares JM; Rodriguez-Martinez A; Burón JA; Alonso-Escolano D; Rodriguez-Morales A;
Appl Health Econ Health Policy; 2008; 6(1):41-53. PubMed ID: 18774869
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
